Your AI-Trained Oncology Knowledge Connection!
Heather McArthur, MD, MPH, FASCO, is the Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical Breast Cancer Research at University of Texas Southwestern (UTSW) Medical Center.
Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.
Heather McArthur, MD, and Debu Tripathy, MD, lead a discussion on risk stratification and optimizing treatment for HER2+ early breast cancer (eBC), followed by a review of standard-of-care systemic therapy regimens in the preoperative/neoadjuvant setting.
Heather Lynn McArthur, MD, MPH, discusses key factors considered in the optimal sequencing of first and second line treatment option in patients with advanced triple-negative breast cancer.
Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.
Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.
Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.
Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.
Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.
A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.
Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.
Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.
Heather Lynn McArthur, MD, MPH, discusses the implications of the phase 3 ASCENT trial in patients with advanced triple-negative breast cancer.
Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.
Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.
Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.
Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.
A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.
Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.
A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.
Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.
Heather McArthur, MD, MPH, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki for second-line treatment in HER2-positive metastatic breast cancer.
After discussing a few more key datasets from the SABCS 2021 Virtual Meeting, expert panelists discuss how they would approach treatment in several subsets of breast cancer.
Focusing on datasets from the SABCS 2021 Virtual Meeting, panelists consider novel approaches to the management of brain metastases in breast cancer.
Expert panelists share their perspectives on metastatic breast cancer management datasets from the SABCS 2021 Virtual Meeting.
